Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.8
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 23222956
Piazza R, et al. (2013) Recurrent SETBP1 mutations in atypical chronic myeloid leukemia. Nat Genet 45, 18-24 23222956
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

Y307-p - PPP2CA (human)
Modsite: VTRRtPDyFl_____ SwissProt Entrez-Gene
Orthologous residues
PPP2CA (human): Y307‑p, PPP2CA iso2 (human): Y253‑p, PPP2CA (mouse): Y307‑p, PPP2CA (rat): Y307‑p, PPP2CA (pig): Y307‑p, PPP2CA (cow): Y307‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  leukemia, acute erythroid leukemias, including erythroleukemia (M6a) and very rare pure erythroid leukemia (M6b)
Relevant cell lines - cell types - tissues:  TF-1 (erythroid)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
SETBP1 (human) increase SETBP1 G870S mutation